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A B S T R A C T
Neonatal infections are a leading cause of childhood mortality in low-resource settings. World Health
Organization guidelines for outpatient treatment of possible serious bacterial infection (PSBI) in neonates and
young infants when referral for hospital treatment is not feasible include intramuscular gentamicin (GEN) and
oral amoxicillin. GEN is supplied as an aqueous solution of gentamicin sulphate in vials or ampoules and requires
health care workers to be trained in dose calculation or selection of an appropriate dose based on the patient's
weight band and to have access to safe injection supplies and appropriate sharps disposal. A simpliﬁed for-
mulation, packaging, and delivery method to treat PSBI in low-resource settings could decrease user error and
expand access to lifesaving outpatient antibiotic treatment for infants with severe infection during the neonatal
period. We developed dissolving polymeric microneedles (MN) arrays to deliver GEN transdermally. MN arrays
were produced from aqueous blends containing 30% (w/w) of GEN and two polymers approved by the US Food
and Drug Administration: sodium hyaluronate and poly(vinylpyrrolidone). The arrays (19 × 19 needles and
500 μm height) were mechanically strong and were able to penetrate a skin simulant to a depth of 378 μm. The
MN arrays were tested in vitro using a Franz Cell setup delivering approximately 4.45 mg of GEN over 6 h.
Finally, three diﬀerent doses (low, medium, and high) of GEN delivered by MN arrays were tested in an animal
model. Maximum plasma levels of GEN were dose-dependent and ranged between 2 and 5 μg/mL. The time
required to reach these levels post-MN array application ranged between 1 and 6 h. This work demonstrated the
potential of dissolving MN arrays to deliver GEN transdermally at therapeutic levels in vivo.
1. Introduction
Neonatal infections, including sepsis, are a signiﬁcant cause of
childhood mortality in low-resource settings; they cause an estimated
26% to 36% of the neonatal deaths that occur globally in low- to
middle-income countries [1,2]. Approximately 421,000 newborns die
each year from sepsis, primarily in low-resource settings [3]. Recently
updated WHO guidelines for outpatient treatment of severe bacterial
infections (sepsis) in neonates (0–28 days old) and young infants
(0–59 days old) when referral for hospital treatment is not feasible in-
clude intramuscular (IM) gentamicin and oral amoxicillin [4].
GEN is a polar, water-soluble compound, which presents very poor
dermal and intestinal permeability. GEN for injection is presented as an
aqueous solution of gentamicin sulphate in vials or ampoules. It has a
narrow therapeutic index and, like other aminoglycosides, it is
potentially ototoxic and nephrotoxic. GEN is excreted almost entirely
unchanged by the kidney, mostly by glomerular ﬁltration and has a
short plasma elimination half-life (2−3 h) in adults with normal renal
function [5]. The elimination half-life of GEN in neonates and children
depends on the patient age [6–8]. Consequently, when this drug is
administered to neonates, careful dose calculation and close monitoring
are required to prevent GEN-induced toxicity. Ideally, close monitoring
of GEN concentration in serum should be conducted, but this is not
commonly available in low-resource settings and is currently not part of
the WHO recommendations speciﬁcally for the outpatient setting.
An easy-to-use, less-invasive, aﬀordable delivery method for GEN
paired with oral amoxicillin has the potential to expand access to life-
saving outpatient antibiotic treatment for infants with severe infection
during the neonatal period. Dissolving MNs are drug delivery systems
with potential to administer GEN while fulﬁlling these requirements
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[9–11]. They are made of safe water-soluble biodegradable or bio-
compatible polymers that act as a matrix containing the drug to be
delivered. Following insertion into skin and subsequent contact with
skin interstitial ﬂuid, MNs dissolve and release the encapsulated drug.
This MN system has successfully delivered numerous substances, in-
cluding low molecular weight (MW) drugs [12,13], macromolecules
[14–17], DNA [18], and vaccines [19–21]. Recently, the work of our
research group has focused on delivering drugs at clinically-relevant
doses using MN arrays [22,23]. McCrudden et al. have formulated and
tested dissolving MNs for delivery of therapeutically-relevant con-
centrations of ibuprofen sodium [24]. In addition, in vitro delivery of a
combination of cardiovascular drugs from a single-dissolving MN array
has recently been investigated by Quinn et al. [25].
GEN delivery by a dissolving MN array could enable administration
in both inpatient and outpatient settings. Compared to parenteral de-
livery, this novel delivery system could reduce training requirements
for calculation of GEN dose and administration, thereby expanding
access to antibiotics to treat neonates with possible serious bacterial
infections, particularly in resource-limited settings. The present work
evaluates the possibility of using dissolving MN arrays for the delivery
of GEN. To the best of our knowledge, this is the ﬁrst study that uses
dissolving MN arrays for the delivery of therapeutically relevant doses
of an antibiotic.
2. Material and methods
2.1. Materials
N-acetylcysteine (NAC), methanol (HPLC grade), poly(vinyl al-
cohol) (PVA) (80% hydrolysed, MW= 9000–10,000 Da), poly(vi-
nylpyrrolidone) (PVP), (MW 360 kDa) and poly(ethylene glycol) (PEG)
(MW 400 Da) were obtained from Sigma-Aldrich (Dorset, UK). Gantrez®
S-97 (PMVE/MA) (a copolymer of methyl vinyl ether and maleic acid,
MW 1,500,000 Da) and plasdone® K-29/32 (PVP) (MW 58 kDa) were
kindly donated by Ashland (Kidderminster, UK). Glycerol bidistilled
(AnalaR NORMAPUR®, 99.5%) and sodium chloride (AnalaR
NORMAPUR® ACS) were obtained from VWR International
(Leicestershire, UK). Gentamicin sulphate and o-phthaldialdehyde
(OPA) were obtained from Tokyo Chemical Industry UK Ltd. (Oxford,
UK). Heparin Sodium (200 units in 2 mL) was provided by Wockhardt®
UK Ltd. (Wrexham, UK). Hyabest®(S) LF-P (sodium hyaluronate 99.9%
purity, MW 250–400 kDa range) was obtained from Kewpie
Corporation Fine Chemical Division (Tokyo, Japan).
2.2. Methods
2.2.1. Fabrication of dissolving MNs
Selected polymers were mixed with GEN and dissolved in deionized
water as potential matrices in the formation of MN. The blend was then
mixed and sonicated at 37 °C for 1–2 h depending on the composition.
The resulting formulations (100 mg) were poured into MN moulds and
positive pressure (3–4 bar) was applied for 15 min to ﬁll the moulds.
MN arrays were allowed to dry for 24 h in a controlled temperature
room at 19 °C. The MN array design used to cast the formulations was
an array consisting of 361 pyramidal needles (19 rows of 19 needles)
each with heights of 500 μm and array area of 0.45 cm2. In addition, a
two-step method was investigated with diﬀerent dissolving MN for-
mulations. For this purpose, aqueous blends (100 mg) containing GEN
were poured into MN moulds. Post-casting, a preformed baseplate,
prepared as detailed in Section 2.2.2, was immediately added on top of
the GEN formulation. Positive pressure (3–4 bar) was applied for
15 min to ﬁll the moulds and then MNs were dried for 24 h at 19 °C.
Once dried, dissolving MNs were visually inspected using a Leica EZ4D
digital light microscope (Leica Microsystems, Milton Keynes, UK). Fig. 1
shows a diagrammatic representation of the fabrication method.
2.2.2. Preparation of ﬁlms as a backing layer for dissolving MNs
Thirty grams of formulation containing 15% w/w PVP (MW
360 kDa) were poured into 10 × 10 cm moulds consisting of a release
liner with the siliconised surface facing upwards secured to a Perspex®
base with wing nuts. Previously, formulation was centrifuged at
3500 rpm (rpm) for 15 min to ensure removal of entrapped air. Films
were placed on a levelled surface and required at least 48 h to dry at
room temperature. Once dried, the ﬁlm was cut into small portions of
approximately 1 cm2.
2.2.3. Microneedle mechanical characterisation
The mechanical strength of dissolving MN arrays was investigated
by using a TA.XT2 Texture Analyser (Stable Micro Systems, Haslemere,
UK) in compression mode, as previously described [26]. Brieﬂy, MN
arrays were attached to the moveable cylindrical probe (length 5 cm,
cross-sectional area 1.5 cm2) of the Texture Analyser and the probe was
programmed to move vertically downward at a rate of 1.19 mm/s. The
test station compressed MN arrays against a ﬂat block of aluminium of
dimensions 9.2 × 5.2 cm, at deﬁned rates for 30 s using a force of
32 N/array [27]. The Leica EZ4D digital microscope was utilised for
visualisation of MN arrays before and after application of the com-
pression load. The heights of individual MNs were measured before and
after testing, using the ruler function of ImageJ® software (US National
Institutes of Health, Bethesda, Maryland, USA) so that the percentage
change in MN height could be calculated using Eq. (1), where, HBC is
the Height before compression and HAC is the Height after compression.
=
−%Compression H H
H
x 100BC AC
BC (1)
In order to evaluate MN insertion, the Paraﬁlm M® (Bemis Company
Inc., Soignies, Belgium) insertion model developed by Larrañeta et al.
was used [27]. MN arrays were inserted using the Texture Analyser, at
32 N/array for 30 s, into eight-layer folded Paraﬁlm M® sheets. After
the insertion, the MN arrays were removed from the polymeric layers.
Paraﬁlm M® layers were unfolded and the number of holes in each layer
was evaluated using the digital microscope and two polarizer ﬁlters.
2.2.4. Dissolution studies and recovery of GEN content from dissolving MNs
Dissolution kinetics and drug content evaluations were carried out
on candidate GEN-loaded dissolving MN arrays to ensure that there
were no compatibility issues between GEN and the polymers selected as
a matrix for MN formation. Individual MNs were placed in a 20 mL
volume of phosphate buﬀered saline (PBS), pH 7.4 in a glass vial. The
time required for complete dissolution of the sample using continuous
stirring at 600 rpm at 37 °C was recorded. Following appropriate dilu-
tions, the GEN content obtained from the dissolving MNs was de-
termined by reversed-phase high-performance liquid chromatography
(RP-HPLC), as detailed in Section 2.2.8.
2.2.5. In-skin dissolution kinetics of dissolving MNs
Optical coherence tomography (OCT) (EX1301 OCT microscope,
Michelson Diagnostics Ltd., Kent, UK) was employed to investigate the
dissolution rate of dissolving MNs in skin, as previously described [28].
Neonatal porcine skin was used as a skin model, due to its similarities to
human skin in terms of general structure, thickness, hair density, pig-
mentation, collagen and lipid composition [29]. Neonatal porcine skin
samples were obtained from stillborn piglets and immediately (< 24 h
after birth) excised and trimmed to a thickness of 500 μm using an
electric dermatome instrument (Integra® Life-Sciences Corporation,
Ratingen, Germany). Skin samples were stored in sealed Petri dishes at
−20 °C until use. Skin samples were shaved and equilibrated in PBS,
pH 7.4 for 15 min prior to use. One section of 500 μm thick neonatal
porcine skin was placed, dermal side facing downwards, onto a 500 μm
piece of Suprasorb® G wound dressing (Lohmann & Rauscher GmbH,
Rengsdorf, Germany). The Suprasorb® G wound dressing was equili-
brated for 48 h in a copious volume of PBS, pH 7.4 at 37 °C prior to use.
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The piece of Suprasorb® G wound dressing was pinned, using drawing
pins, into a Styrofoam™ platform which was wrapped in aluminium foil
and Paraﬁlm M®. The skin was pinned on top of these wound dressing
sections. Dissolving MN arrays were adhered to a piece of Sellotape®
and manually applied into the skin. This experimental design main-
tained a hydrated membrane. The swept-source Fourier domain OCT
system has a laser centre wavelength of 1305.0 ± 15.0 nm, facilitating
real-time high-resolution imaging of the upper skin layers (7.5 μm lat-
eral and 10.0 μm vertical resolution). The skin was scanned at a frame
rate of up to 15 B-scans (2D cross-sectional scans) per second (scan
width = 2.0 mm). The 2D images were examined using the imaging
software ImageJ®. To allow diﬀerentiation between MN and skin layer,
false colours were applied to images using Microsoft® PowerPoint 2016
(Microsoft Corporation, Redmond, Washington, USA). OCT images
were captured at designated time points over the course of a 1 h ex-
periment.
2.2.6. In vitro permeation study of GEN from dissolving MNs
Transdermal permeation of GEN released from dissolving MNs was
investigated in vitro using Franz diﬀusion cells, as described previously
[14,24]. A section of the neonatal porcine skin (350 μm thick), obtained
as described above, was secured to the donor compartment of the dif-
fusion cell using cyanoacrylate glue with the stratum corneum facing
upwards in the donor compartment. MNs were inserted into the centre
of the skin section by applying manual pressure for 30 s to a syringe
plunger, with the ﬂat end pressing on the baseplate. A stainless-steel
cylinder (diameter 11.0 mm, 5.0 g mass) was then placed on top of the
MNs to hold them in place. The donor compartments were set onto the
receptor compartments of the Franz cells, which were sealed using
Paraﬁlm M® to reduce evaporation. In the receiver solution, PBS
(pH 7.4) was thermostatically maintained at 37 ± 1 °C and stirred at
600 rpm. Samples (≤200 μL) were removed from the sampling arms of
the Franz cells at predetermined time intervals (15 min, 30 min, 1 h,
2 h, 3 h, 4 h, 5 h, 6 h and 24 h) using 1 mL syringes with 8 cm needles
and 200 μL of PBS was subsequently added to replace the volume taken.
Derivatisation of the samples was carried out using volumes of 100 μL
of sample: 100 μL of derivatising reagent. Samples were centrifuged for
10 min and then ﬁltered through 0.2 μL syringe ﬁlters. Finally, the
samples were analysed by RP-HPLC.
2.2.7. In vivo delivery of GEN
An in vivo experiment using dissolving MNs was carried out to
evaluate proﬁles of GEN in plasma after the application of MN arrays.
Female Sprague-Dawley rats weighing 208.65 ± 21.48 g and aged
10 weeks were acclimatised to laboratory conditions for a 7-day period.
Animals were separated in four groups (n= 10 per group) (Fig. 2). In
the control group (A), animals received an IM injection of GEN based on
individual rat weight, 7.5 mg/kg of gentamicin sulphate to mimic the
WHO higher neonatal dose [4]. Thus, a solution of 15 mg/mL of GEN
was freshly prepared in sterile water for injection. The IM injection was
given into the muscles of the thigh and the volume injected was
≤100 μL. The transdermal treatments groups were denominated: low
dose (B), medium dose (C) and high dose (D), in which rats were treated
with one, two or four dissolving MNs, respectively. Dissolving MN ar-
rays were prepared to contain an average of 30 mg of GEN per array.
Animals were anaesthetized using gas anaesthesia (2–4% isoﬂurane
in oxygen) and the backs of the rats were shaved using an animal hair
clipper and hair removal cream, prior to application of MNs. Dissolving
MNs were secured onto an open “frame” of adhesive foam and were
applied using ﬁrm ﬁnger pressure onto a pinched section of skin on the
back of the animals. To keep the MN array in place, an occlusive
dressing layer, Tegaderm™ (3 M, St Paul, Minnesota, USA), was placed
on top of the dissolving MNs, and Micropore™ tape (3 M UK Plc,
Bracknell, Berkshire, UK) was used to wrap the back of the animals.
Blood samples (≤200 μL) were collected into heparinised tubes at de-
signated time points: 1, 2, 4, 6 and 24 h via tail vein bleeds. The MN
arrays were kept in place for 24 h. It was not possible to track plasma
level of GEN at each time point from the same animal due to restrictions
in blood sampling volumes by our Institutional Project Licence. To
overcome this, blood samples were taken from the ﬁrst ﬁve rats at 1 h
and 4 h. The other ﬁve animals were bled at 2 h and 6 h and all animals
(n= 10) were sampled at 24 h. After collection of rat blood, plasma
Fig. 1. Diagrammatic representation of MN fabrication process in (A) one-step and (B) two-step.
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separation was performed by centrifuging the blood at 3000 relative
centrifugal force (RCF) for 10 min at 4 °C in a refrigerated centrifuge (Z
216 MK, HERMLE Labortechnik GmbH, Wehingen, Germany). Plasma
samples were collected in 0.5 mL microtubes and stored in a freezer at
−80 °C prior to analysis. To extract GEN, plasma samples were vor-
texed for 10 s and transferred to Amicon® Ultra-0.5 centrifugal ﬁlter
devices (10 kDa) (EMD Millipore Corporation, Billerica, Massachusetts,
USA). Samples were centrifuged at 15,000 RCF for 30 min at 4 °C to
remove proteins prior to HPLC analysis. A pre-column derivatisation
was carried out with the ﬁltered samples obtained after centrifugation.
In all cases, the ratio of derivatising reagent mixture and samples was
1:1, depending on the volume of sample recovered. Approval for animal
experiments was obtained from the Committee of the Biological
Research Unit, Queen's University Belfast. The work was carried out
under Project Licence PPL 2794 and Personal Licence PIL 1466. All in
vivo experiments were conducted according to the policy of the fed-
eration of European Laboratory Animal Science Associations and the
European Convention for the protection of vertebrate animals used for
experimental and other scientiﬁc purposes, with implementation of the
principles of the 3Rs (replacement, reduction, and reﬁnement). Values
for area under the curve (AUC) were calculated by the trapezoidal
method using GraphPad Prism®.
2.2.8. GEN analytical method
Chemical derivatisation of GEN components was accomplished to
increase sensitivity and allow low level quantiﬁcation by RP-HPLC. The
derivatisation of GEN was carried out using o-phthaldialdehyde (OPA)
and N-acetylcysteine (NAC) as reagents by slight modiﬁcation of the
procedure developed by Kowalczuk et al. [30]. Brieﬂy, the derivatisa-
tion reagents were prepared by dissolving 20 mg of OPA in 1 mL of
methanol and 100 mg of NAC was dissolved in 1 mL of deionized water.
To the mixture of OPA and NAC, 8 mL of 0.05 M borate buﬀer (pH 9.3)
were added. OPA and NAC were freshly prepared for each derivatisa-
tion. For GEN quantiﬁcation, 500 μL of sample was reacted with 500 μL
of derivatising reagent mixture in microtubes in a water-bath at 50 °C
for 20 min. After cooling, samples were analysed by RP-HPLC. The
mobile phase was a mixture of methanol and an aqueous solution of
0.02 M of sodium hexanesulphonate and glacial acetic acid (65.5:33.5,
v/v), with a ﬂow rate of 1 mL/min, an injection volume of 40 μL and a
run time of 25 min per sample. GEN was detected using ﬂuorescence
detection with excitation wavelength set at 328 nm and emission at
423 nm. The gain was optimal at a reading of 12. Phase separation was
performed on a Phenomenex® SphereClone™ 5 μm ODS (1) column
(150 mm× 4.60 mm with 5 μm packing; Phenomenex, Cheshire, UK)
at ambient temperature. All analytical runs were preceded by a security
guard cartridge of matching chemistry. Data acquisition and analysis
were performed using Agilent Rapid Res® software (Agilent Technolo-
gies UK Ltd., Stockport, UK). All samples were centrifuged at
14,000 rpm using an Eppendorf MiniSpin® centrifuge (Eppendorf UK
Limited, Stevenage, UK) for 10 min prior to HPLC analysis. Unknown
concentrations of test samples were calculated using external standards.
The HPLC method for quantiﬁcation of GEN substances in PBS and
rat plasma were developed and validated in accordance with the
International Committee of Harmonisation Q2(R1) guidelines for vali-
dation of analytical procedures [31]. Table 1 shows the slope, y-inter-
cept and coeﬃcient of determination (R2 value) obtained from least
squares linear regression analysis, followed by correlation analysis of
the calibration plots for derivatised GEN in PBS and plasma.
2.2.9. Statistical analysis
All data were expressed as means ± standard deviation. The sta-
tistical analyses were performed using GraphPad Prism® version 5.3
(GraphPad Software, San Diego, California, USA). Where appropriate,
the Mann-Whitney U test was performed for comparison of two groups,
when n < 5. The unpaired t-test was used for comparison of two
groups, when n > 5 and data were normally distributed. The Kruskal-
Wallis test with post-hoc Dunn's test was used for comparison of mul-
tiple groups. In all cases, p < 0.05 was used to denote statistical sig-
niﬁcance.
Fig. 2. Schematic representation showing the four treatment groups investigated in the in vivo experiment. (A) IM administration of GEN, 7.5 mg/kg. Transdermal application of (B) one,
(C) two and (D) four MN arrays to the hairless back of the animals and the setup used to ensure the MNs were kept in place.
Table 1
Calibration curve properties for derivatised GEN quantiﬁcation in PBS, pH 7.4 and rat
plasma and limits of detection (LoD) and quantiﬁcation (LoQ) for GEN.
Slope y-Intercept R2 LoD (μg/mL) LoQ (μg/mL)
PBS, pH 7.4 291.46 −2.366 0.9987 0.049 0.149
Rat plasma 670.98 −92.982 0.9955 0.099 0.301
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3. Results
3.1. Formulations investigated in the production of GEN-loaded dissolving
MNs
Several polymers were investigated to evaluate their potential as
matrices in the formation of dissolving MNs loaded with a high con-
centration of GEN. Some of the selected polymers, such as PVP high
MW (360 kDa) or PVA were not able to form a homogeneous aqueous
blend with a high concentration of GEN. In contrast, sodium
hyaluronate (HA), MW 250–400 kDa range, in combination with low
MW PVP (58 kDa) formed the most promising formulations. Low con-
centrations of glycerol were used in some formulations as plasticisers.
Dissolving MNs that appeared to be fully formed upon visual ex-
amination under a light microscope (Table 2) were chosen for further
dissolution and drug content evaluations.
3.2. Mechanical characterisation of dissolving MN arrays
Dissolving MNs prepared with the selected formulations were used
Table 2
Formulations selected for the production of GEN loaded dissolving MNs.
Formulation Composition (% w/w) MN morphology
GEN HA PVP Glycerol
F1 30 3.4 1 –
F2 30 3 1 0.5
F3 30 3 2 0.5
F4 30 5 5 –
F5 30 5 2.5 –
F6 30 3.4 1 0.5
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to investigate the eﬀects of compression tests on the heights of in-
dividual needles on the MN arrays. Fig. 3A shows the reduction in MN
height for all the selected formulations. The application force of 32 N/
array reduced the height of all dissolving MNs. The percent reduction in
MN height for formulation F2 and F5 was< 9% and< 5%, respec-
tively. The percent reduction in the original MN height was< 2% for
formulations F3 and F6 and< 3% for formulations F1 and F4. The
percent reduction of F2 was signiﬁcantly diﬀerent compared to all other
formulations (p= 0.0084).
The percentage of holes created in each Paraﬁlm M® layer for dif-
ferent dissolving MN formulations is shown in Fig. 3B. The in vitro in-
sertion depths obtained for formulations tested showed a similar trend
and all were capable of piercing three layers of Paraﬁlm M®. The
average thickness of a Paraﬁlm M® layer is 126 ± 7 μm; this suggests
that MNs were inserted up to 378 μm of the total 500 μm height, ap-
proximately 75.6% of MN tip height. These results indicate that total
needle length inserted correlated with previously reported studies,
where the insertion was equivalent to 60% of the total needle length
[27,32]. However, it is important to note that formulations F2, F3, F4
and F5 were not selected for further investigation because these for-
mulations showed some individual needles remained in the Paraﬁlm
M® after the insertion test.
3.3. Fabrication of MN in two-steps
After optimising the formulation of the MN, a two-step manu-
facturing process was tested to provide a degree of ﬂexibility to the
baseplate of the MN array. Fig. 4A and B shows a two-layered MN array.
Formulation F6, which contained 0.5% glycerol to reduce fragility,
and prepared with a baseplate made of 15% w/w of PVP, MW 360 kDa:
2.5% glycerol, showed a remarkable reduction of recovery of drug
compared to F1 fabricated in two-step which contained no glycerol in
the needles or baseplate (Fig. 4C). The percentage of GEN recovery was
found to be 89.56 ± 8.82% and 57.27 ± 9.38% for the two-layered
MNs prepared using F1 and F6, respectively. However, the percentage
of GEN recovery was 100.7 ± 9.69% and 89.56 ± 8.82% for for-
mulations F1 and F6 prepared as a single layer. Besides, MNs containing
glycerol in the preformed baseplate became ﬂexible, losing mechanical
strength, after 10 days of storage at room temperature. This was un-
surprising given the highly hygroscopic nature of glycerol. Conse-
quently, F6 was discarded. MN arrays prepared in two-step, made of F1
in the needles and 15% w/w of PVP high MW (360 kDa) as a preformed
baseplate showed adequate recovery of GEN and desirable mechanical
strength. Fig. 4D displays the in vitro dissolution kinetics of F1 in neo-
natal porcine skin using OCT. MN arrays prepared from F1 eﬀectively
pierced the skin and the in-skin MNs dissolved in the ﬁrst ﬁve min.
After 1 h, skin was completely recovered. Consequently, this formula-
tion was taken forward for in vitro permeation studies to investigate the
eﬃcacy of drug delivery. Formulation F1 retained its mechanical
strength properties after storage in a plastic container covered with
aluminium foil at 19 °C for> 4 weeks.
3.4. In vitro permeation study of GEN from dissolving MNs
Two-layered MNs were fabricated from formulation F1 containing
approximately 30 mg of GEN per array. The amount of GEN loaded in
the needles was approximately 4.8 mg, calculated considering the
density of the formulation and the volume of the 361 square pyramidal
needles. These arrays were used to evaluate the in vitro permeation of
GEN across neonatal porcine skin (Fig. 5). Dissolving MNs made of F1
delivered 1.53 ± 0.28 mg of GEN in 1 h, 3.08 ± 0.5 mg of GEN in 3 h
(10.25%) and a total of 22.56 ± 5.36 mg of GEN in 24 h (75%), de-
livered across the neonatal porcine skin. All GEN loaded in the needles
was delivered within 6 h and most of the GEN content forming the
baseplate was delivered within 24 h.
3.5. In vivo delivery of GEN
The in vivo plasma proﬁle of GEN post-IM injection is shown in
Fig. 6A. Therapeutic levels of GEN in plasma (5.72 ± 0.35 μg/mL)
were achieved within an hour following IM injection. The mean plasma
level of GEN progressively decreased to 2.52 ± 0.49 μg/mL at 2 h,
after which most concentrations were found to be below the LoQ.
The mean concentration of GEN in plasma for the low dose treat-
ment group was 1.13 ± 0.42 μg/mL at 1 h, 1.58 ± 1.31 μg/mL at 2 h
and 1.80 ± 1.22 μg/mL at 4 h. A maximal concentration of GEN
(2.21 ± 1.46 μg/mL) was achieved at 6 h and then was slightly re-
duced (0.93 ± 1.11 μg/mL) at 24 h (Fig. 6B).
The mean concentration of GEN in plasma for the medium dose
treatment group increased from 1.83 ± 1.13 μg/mL at 1 h to
5.34 ± 4.23 μg/mL at 2 h. The mean GEN concentration in plasma
dropped to 2.37 ± 1.81 μg/mL at 4 h, increased again to
4.58 ± 4.11 μg/mL at 6 h and dropped to 1.68 ± 0.94 μg/mL at 24 h
(Fig. 6C).
The plasma proﬁle for the high dose treatment group is presented in
Fig. 6D. A therapeutic concentration of GEN in plasma was achieved
within an hour (4.30 ± 1.47 μg/mL). After 1 h, the mean drug con-
centration in plasma dropped and remained consistently< 3 μg/mL for
subsequent sampling points.
The IM control treatment group presented the highest plasma con-
centration of GEN at 1 h (Cmax = 5.72 ± 0.35 μg/mL) (Fig. 7). The
Cmax for the IM control group was statistically higher than those for the
low dose Cmax (p= 0.0008) and the high dose treatment group Cmax
(p= 0.0159). However, the maximum plasma concentration of GEN for
the medium dose transdermal treatment group was not diﬀerent com-
pared to the IM control Cmax (p= 1.000). Pharmacokinetic parameters
are presented in Table 3.
As expected, the lowest GEN Cmax was observed following ad-
ministration of an individual dissolving MN patch and the time of
maximum plasma concentration (Tmax) was 6 h following application.
The comparison between Cmax of the transdermal groups was not
statistically signiﬁcant (p= 0.1629). However, increasing the number
of GEN MN arrays resulted in an earlier Tmax.
Fig. 3. (A) Comparison of percentage of MN height reduc-
tion of dissolving MN formulations tested, observed fol-
lowing the application of a force of 32 N/array (means
+ S.D., n= 4). (B) Percentage of holes created in each
Paraﬁlm M® layer following insertion of dissolving MN
formulations investigated. MN arrays used were 19 × 19
with a needle height of 500 μm, base width of 300 μm and a
base interspacing of 50 μm (means + S.D., n= 4).
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4. Discussion
Despite the limitation of drug loading in dissolving MNs, several
studies have highlighted the ability of this platform to enhance trans-
dermal delivery of an extensive range of drug molecules [9,10]. The
initial objective of this work was to formulate well-formed MNs using
biocompatible materials approved by the US Food and Drug Adminis-
tration (FDA) with high drug loading of GEN. Ideal GEN MN formula-
tions should have suﬃcient mechanical strength for a successful ap-
plication into the skin by the patient or a healthcare provider, rapidly
dissolve, and yield high drug recovery. The geometry of the MN and
physicochemical properties of the drug and polymers aﬀect mechanical
strength [10].
We formulated numerous dissolving MNs using water-soluble bio-
compatible or biodegradable polymers to investigate their compat-
ibility with a high dose of GEN (30% w/w). Some polymers, such as
PVP [25], PVA [33,34], sodium hyaluronate [35,36] and Gantrez®
copolymers [12,24,25,37,38] have frequently been used as matrices in
the formation of dissolving MNs. PVP of high MW (360 kDa) and PVA
(MW 9–10 kDa), showed incompatibilities with high doses of GEN. In
contrast, MNs formulated using low concentrations of sodium hyalur-
onate (MW 300 kDa) and PVP (MW 58 kDa) formed MNs that, upon
visual inspection, were fully formed. Plasticisers, such as glycerol and
PEG 400, were used to decrease MN brittleness, a property that can
prevent successful insertion in skin and thus inhibit drug delivery.
Glycerol is commonly incorporated into ﬁlms to overcome brittleness
[39,40]. Moga et al. have reported the use of plasticisers such as castor
oil, Tween® 80, glycerol, PEG 400 and trimethyl citrate to impart
ﬂexibility to the blends of a PVP/poly(vinylacetate) copolymer used as
a substrate for dissolving MNs [41]. Among all the prepared formula-
tions, a few were selected based on the formation of intact and re-
producible MNs possessing rapid dissolution rates (Table 2). The main
compounds used to formulate these arrays were PVP, HA and glycerol.
This study was conceived as a proof of concept and the main ob-
jective was to explore the possibility of administering therapeutically
relevant doses of GEN using dissolving MNs. To the best of our
knowledge there are no previous articles describing similar drug de-
livery systems. Accordingly, we maximise the amounts of GEN loaded
in the MN arrays. The arrays were manufactured containing GEN in the
needle tips and in a small baseplate. In this way GEN can be adminis-
tered from the needle tips and subsequently from the baseplate. The
drug contained in the baseplate can permeate through the created pores
Fig. 4. Digital pictures showing two-layered MN array taken with (A) the Leica EZ4D digital microscope and (B) the Keyence VHX-700F digital microscope (Keyence, Milton Keynes, UK).
(C) Comparison of percentage recovery of GEN from dissolving MNs prepared from F1 and F6 in one-step and two-step (means ± S.D., n= 3). (D) Representative OCT images showing in
vitro dissolution kinetics of a 19 × 19 MN array prepared using F1 and inserted manually in neonatal porcine skin. False colours were applied to the skin and MNs. The original OCT
images can be found on the Supplementary content (Fig. S1). The white scale bar at top right represents a length of 1 mm.
Fig. 5. In vitro permeation proﬁle of GEN across 350 μm neonatal porcine skin when
delivered from dissolving MNs made of formulation F1 over a 24 h period.
Means ± S.D., n= 4.
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as suggested by McCrudden et al. [24].
The delivery of the drug via dissolving MNs depends on their ability
to pierce the stratum corneum; dissolving MNs must therefore possess
suﬃcient mechanical strength. Accordingly, a range of mechanical
characterisation tests has been developed to test their mechanical
strength and insertion characteristics. Such tests include MN insertion
into skin [42], MN compression test [26] and OCT [28], among others.
Lutton and co-workers have recently highlighted an urgent need for
consistency to characterise MN products in order to demonstrate MN
strength and insertion [43]. The in vitro insertion test developed by
Larrañeta et al. was used to assess the ability of the dissolving MNs to
pierce a skin simulant, Paraﬁlm M®, thus avoiding dissolution of the
MNs in biological tissue. The mechanical testing of dissolving MN
provided information about which concentrations of HA and PVP
yielded the best strength and insertion capabilities. In summary, for-
mulations investigated showed to form robust needles that were not
fractured upon compression. However, some formulations were deemed
unsuitable for further investigation because needles tips were not en-
tirely formed and also some individual needles retained in the Paraﬁlm
M® post-insertion test. Furthermore, dissolving MNs were prepared in
two-step to provide certain ﬂexibility to the baseplate of the MN arrays.
Ideally, the baseplate should have some inherent ﬂexibility to allow
conformation to the skin surface without cracking; a variety of tech-
niques have been used to fabricate dissolving MNs in a two-step process
to localise the active compounds to the needles, thereby reducing drug
waste [15,17,18,44,45].
The rate of dissolution of dissolving MNs in-skin depends on the
solubility in water of the polymers and drug studied and also the
composition [10]. The non-invasive technique based on light reﬂection,
OCT, was used to investigate the in-skin dissolution kinetics of dissol-
ving MNs. This technique has been widely used in clinical care, pre-
dominantly for ophthalmic applications, and in research, providing
high-resolution cross-sectional images of the object of study [46]. A
number of studies have highlighted the potential of OCT as a valuable
tool to assess MN insertion in skin, allowing measurement of the MN
depth and visualisation of microchannels created in skin [26,28,47,48].
Likewise, OCT has been used for in vivo visualisation of dissolution of
Fig. 6. (A) In vivo plasma proﬁle of GEN following IM injection of gentamicin sulphate dissolved in sterilised water for injections (dose was 7.5 mg/kg). Means ± S.D., n= 5 at 1 h, 2 h,
4 h and 6 h; n= 10 at 24 h. (B) Transdermal delivery by using one dissolving MN (low dose). Means ± S.D., n= 5 at 1 h, 2 h and 6 h; n= 4 at 4 h; n= 10 at 24 h. (C) Transdermal
delivery by using two dissolving MNs (medium dose). Means ± S.D., n= 4 at 1 h, 2 h, 4 h and 6 h; n= 9 at 24 h. (D) Transdermal delivery by using four dissolving MNs (high dose).
Means ± S.D., n= 4 at 1 h; n= 5 at 2 h, 4 h and 6 h; n= 10 at 24 h. Dashed lines represent limit of quantiﬁcation for GEN (LoQ= 0.30 μg/mL).
Fig. 7. Comparison of mean peak plasma concentrations of GEN (Cmax) following IM
injection and transdermal delivery of GEN at increasing doses. Means ± S.D., n= 5 for
the control group and the low dose and n= 4 for medium and high dose. (ns) indicates p
values > 0.05, (*) indicates p values≤ 0.05 and (***) indicates p values≤ 0.001.
Table 3
Pharmacokinetic parameter of GEN applied to rats for the IM injection and the three
transdermal treatments groups: low dose, medium dose and high dose. Means ± S.D.,
n= 5 for the IM group and low dose and n= 4 for medium and high doses.
Parameter IM injection Low dose Medium dose High dose
AUC (μg. h/mL) 12.03 37.05 74.58 56.13
Tmax (h) 1 6 2 1
Cmax (μg/mL) 5.72 ± 0.35 2.21 ± 1.46 5.34 ± 4.23 4.30 ± 1.47
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MNs into murine skin [16,17] and in situ dissolution of MNs into neo-
natal porcine skin [28]. The in vivo swelling of hydrogel-forming MNs
has also been examined using OCT in the skin of human volunteers
[49–51] and in vitro in neonatal porcine skin [52]. The GEN-loaded
dissolving MNs were robust enough to penetrate skin in vitro and the
complete dissolution of the in-skin MNs was achieved in the ﬁrst ﬁve
min.
The in vitro permeation studies carried out with two-layered dis-
solving MNs (F1) across neonatal porcine skin via the Franz diﬀusion
cell technique deduced that 14.85% (4.45 mg) of GEN loadings were
delivered over a 6 h experimental period and approximately 75% of the
GEN contained in the MN array was successfully delivered in 24 h. As
expected, GEN contained in the baseplate was delivered through the
created pores after the dissolution of the needle tips. On the other hand,
the results obtained in the in vivo experiment conﬁrmed that the use of
dissolving MN arrays enabled transdermal delivery of GEN. It is im-
portant to highlight that once the GEN Cmax was reached, regardless of
the dose, GEN levels in plasma were shown to be sustained over time.
This may be indicative of drug still being released from the MN patch
while concurrently being cleared from the body of the animals. It is
important to notice that GEN is contained in the needle tips and in the
baseplate of the MN array. And after the dissolution of the needle tips,
GEN continued to be administered from the baseplate as the patches
were covered by an occlusive dressing. Consequently, MNs provide a
sustained release and that explains why the AUC obtained for MN ad-
ministration are higher than the AUC obtained for the IM injection.
Besides, this explains why the Tmax is higher for the lower GEN dose
administered using MNs. In this case, GEN delivered from the baseplate
is required to reach the higher maximum drug levels. The patches with
higher GEN doses contained enough drug in the needle tips to achieve
the maximum drug levels within shorter periods of time.
As described before, this study was planned as a proof of concept
and after evaluating the in vivo results it is obvious that the system
should be optimized for further applications. In order to achieve a rapid
delivery and prevent the sustained delivery the MN arrays can be
manufactured containing the drug only in the needle tips. In this way,
the drug can be administered in a quicker way preventing sustained
release of GEN from the baseplate. Thus, drug clearance in animals will
require further investigation. Regardless of the number of MN arrays
used, it was observed that MNs were completely dissolved when arrays
were removed from the back of the animal. Transient mild erythema
was observed after removing the patches and, in line with previous
publications, the erythema disappears quickly after MN removal
[53,54]. It is worth noting that concentrations of the HA, a FDA-ap-
proved biodegradable and biocompatible polymer, and low MW PVP, a
biocompatible FDA-approved pharmaceutical excipient, were low in
the formulation investigated. However, elimination of both polymers
from the body should be investigated.
The therapeutic plasma levels of GEN in humans ranges between 4
and 10 μg/mL [8,55]. GEN exhibits a concentration-dependent bacter-
icidal eﬀect, in which a linear relationship exists among higher peaks,
the minimum inhibitory concentration ratio and improved clinical re-
sponse [6]. With once-daily administration, higher peak concentrations
may be observed. Peak and trough GEN serum concentrations should be
therapeutically eﬀective, while being nontoxic. Prolonged peak serum
concentrations above 10–12 μg/mL and trough serum concentrations
above 2 μg/mL should be avoided, as these levels may be potentially
toxic [8]. Predicting pharmacokinetics from animals to humans require
further investigation. However, one can prudently extrapolate the in-
formation obtained from the animals and approximate the patch size
necessary to use in neonates. A neonate has an average body weight of
3 kg, which is approximately 15 times greater than the average body
weight of rats used in this experiment (0.209 kg). For the medium dose
treatment group, which applied two MN arrays of size 0.45 cm2,
the< 1 cm2 MN patch was capable of delivering GEN achieving a mean
plasma concentration of 5.34 μg/mL at 2 h upon application.
Consequently, a patch size of approximately 15 cm2 could potentially
deliver therapeutic doses of GEN and should be removed after 3 h to
avoid possible GEN side eﬀects. For the high dose treatment, the GEN
Cmax was observed at 1 h post-application, reaching therapeutic levels.
Thus, the high dose treatment group yielded a more rapid delivery of
GEN, and the data showed less variability than the data obtained from
the medium dose treatment group when the GEN Cmax was observed.
Therefore, a patch size not larger than 30 cm2 could potentially deliver
therapeutic doses of GEN in newborns and should be removed after
1–2 h in order to avoid oto- and nephrotoxicity. Nevertheless, Tanira
et al. have reported shorter half-lives and larger clearances of GEN in
young rats (2–3 months old) compared to older rats (22–24 months old)
[56]. This is unsurprising due to small mammals such as rats tend to
metabolise some drugs more rapidly than larger mammals [57,58]. In
addition, GEN pharmacokinetics is aﬀected by renal function and
neonates present reduced glomerular ﬁltration rate. Therefore, it is
expected that neonates have lower renal clearance of GEN compared to
older infants and adults [59–62]. Considering this, the estimated patch
sizes could probably be reduced signiﬁcantly. A transdermal patch of
such size could potentially be applied to the thigh or to the upper back
of the neonate, as both sites provide a relatively ﬂat surface. The
manual application of larger than 1 cm2 MN patches is feasible as
shown recently by Ripolin et al. [53]. The acceptability and feasibility
of delivery of GEN MN arrays at these sites should be assessed. A range
of patch sizes would be required according to diﬀerent weight cate-
gories. MN arrays allow the delivery of GEN without the need of in-
jections and could enable expanded access to treatment outside of in-
patient facilities. Additionally, this approach reduces dangerous sharps
waste as dissolving MN arrays are self-disabling and cannot be re-
inserted into another patient after being used [11]. Future work will
focus on optimisation of the two-step method to cast only GEN for-
mulation in the tips of the MN arrays. A transdermal MN patch design
with targeted GEN loading may reduce the risk of prolonged adminis-
tration of GEN and toxicity if the patch is inadvertently worn too long.
5. Conclusion
The work presented here reports the successful formulation and
mechanical characterisation of dissolving MN arrays containing the
antibiotic, GEN. Furthermore, in in vivo experimentation, ther-
apeutically relevant doses of the antibiotic were delivered to rats,
highlighting the potential for exploitation of this delivery route for GEN
administration. This promising technology could simplify administra-
tion of GEN in developing countries, thus expanding access to lifesaving
outpatient antibiotic treatment for infants with severe infection during
the neonatal period. This is an exploratory study and before this tech-
nology can be applied to patients several studies need to be conducted
such as a formulation stability evaluation, a comprehensive pharma-
cokinetic study and patient usability/acceptability study. Finally,
evaluating the potential pathway to commercialisation of this tech-
nology, and the cost of GEN-loaded MN arrays when manufactured at
scale, will also be important factors in the potential health impact of
this delivery approach in resource-limited settings.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jconrel.2017.07.032.
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